Breaking the barriers: Overcoming cancer resistance by targeting the NLRP3 inflammasome
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.17352 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Nazanin Pazhouhesh Far und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Faculty of Advanced Science and Technology, Tehran Medical Science, Islamic Azad University, Tehran, Iran. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Neoplasms, Inflammasomes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 185 Literaturangaben.
Abstract (Originalsprache)
Inflammation has a pivotal role in the initiation and progression of various cancers, contributing to crucial processes such as metastasis, angiogenesis, cell proliferation and invasion. Moreover, the release of cytokines mediated by inflammation within the tumour microenvironment (TME) has a crucial role in orchestrating these events. The activation of inflammatory caspases, facilitated by the recruitment of caspase‐1, is initiated by the activation of pattern recognition receptors on the immune cell membrane. This activation results in the production of proinflammatory cytokines, including IL‐1β and IL‐18, and participates in diverse biological processes with significant implications. The NOD‐Like Receptor Protein 3 (NLRP3) inflammasome holds a central role in innate immunity and regulates inflammation through releasing IL‐1β and IL‐18. Moreover, it interacts with various cellular compartments. Recently, the mechanisms underlying NLRP3 inflammasome activation have garnered considerable attention. Disruption in NLRP3 inflammasome activation has been associated with a spectrum of inflammatory diseases, encompassing diabetes, enteritis, neurodegenerative diseases, obesity and tumours. The NLRP3 impact on tumorigenesis varies across different cancer types, with contrasting roles observed. For example, colorectal cancer associated with colitis can be suppressed by NLRP3, whereas gastric and skin cancers may be promoted by its activity. This review provides comprehensive insights into the structure, biological characteristics and mechanisms of the NLRP3 inflammasome, with a specific focus on the relationship between NLRP3 and tumour‐related immune responses, and TME. Furthermore, the review explores potential strategies for targeting cancers via NLRP3 inflammasome modulation. This encompasses innovative approaches, including NLRP3‐based nanoparticles, gene‐targeted therapy and immune checkpoint inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Faculty of Advanced Science and Technology, Tehran Medical Science, Islamic Azad University, Tehran, Iran.
- Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- Medical Campus, Xi'an Jiaotong University, Xi'an, China.
- Department of Pathology, Faculty of Anatomical Pathology, Ghaem Hospital, University of Medicine, Mashhad, Iran.
- Department of Biology, College of Science, Qaemshahr Branch, Islamic Azad University, Qaem Shahr, Iran.
- Department of Ergonomics, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Zitieren
APA
Pazhouhesh Far, N., Hajiheidari Varnousafaderani, M., Faghihkhorasani, F., Etemad, S., Abdulwahid, A. R. R., Bakhtiarinia, N., Mousaei, A., Dortaj, E., Karimi, S., Ebrahimi, N., & Aref, A. R. (2025). Breaking the barriers: Overcoming cancer resistance by targeting the NLRP3 inflammasome. British Journal of Pharmacology. https://doi.org/10.1111/bph.17352
Vancouver
Pazhouhesh Far N, Hajiheidari Varnousafaderani M, Faghihkhorasani F, Etemad S, Abdulwahid ARR, Bakhtiarinia N, et al. Breaking the barriers: Overcoming cancer resistance by targeting the NLRP3 inflammasome. British Journal of Pharmacology. 2025. doi:10.1111/bph.17352
BibTeX
@article{PazhouheshFar2025,
author = {Pazhouhesh Far, Nazanin and Hajiheidari Varnousafaderani, Mahsa and Faghihkhorasani, Ferdos and Etemad, Sareh and Abdulwahid, Al-Hasnawi Rasool Riyadh and Bakhtiarinia, Negar and Mousaei, Afsaneh and Dortaj, Elahe and Karimi, Soroush and Ebrahimi, Nasim and Aref, Amir Reza},
title = {Breaking the barriers: Overcoming cancer resistance by targeting the NLRP3 inflammasome},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.17352}
}
EUVIMED